Want to see FR:ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
€104.70
-€0.19(-2.81%)
At close: 4:00 PM EST
€104.70
-€0.19(-2.81%)
Day’s Range― - ―
52-Week Range€6.55 - €139.00
Previous CloseN/A
Volume4.35K
Average Volume (3M)99.97K
Market Cap
€10.20B
Enterprise Value€6.57B
Total Cash (Recent Filing)€530.38M
Total Debt (Recent Filing)€45.89M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Sep 21, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding79,782,940
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€125.00Price Target Upside19.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.32
Revenue Forecast (FY)€3.81M
Bulls Say, Bears Say
Bulls Say
Improved Balance Sheet And Low LeverageThe 2025 balance sheet improvement and ~7% debt-to-equity indicate materially lower refinancing pressure and greater capacity to fund near-term clinical programs. Durable lower leverage reduces short-term liquidity risk and gives management flexibility to execute trials without immediate distress financing.
High Historical Gross MarginsNear-100% gross margins when revenue occurred imply favorable product economics typical of small-molecule therapeutics. If clinical development leads to commercialization, these structural margins could support profitable scaling and attractive long-term unit economics despite current scale limitations.
Focused Clinical-stage R&D PipelineA clear therapeutic focus on obefazimod and chronic inflammatory indications concentrates resources on high-value outcomes. This focused pipeline and R&D orientation improve execution clarity and allow efficient allocation of capital to pivotal trials, which is durable if clinical readouts progress positively.
Bears Say
Persistent High Cash BurnSustained negative operating and free cash flow indicates the business cannot self-fund development; this structural cash burn forces recurring external financing, raises dilution risk, and constrains the company's ability to advance multiple programs simultaneously without prioritization or partnership.
Widening Net Losses And No Recent RevenueDeepening annual losses coupled with a drop to zero revenue in 2025 signal the firm remains pre-commercial and far from profitability. Over the medium term this erodes internal funding capacity and increases dependence on clinical success or external deals to create a sustainable revenue base.
Reliance On External Financing And Balance Sheet SwingsHistorical volatility in leverage demonstrates reliance on episodic capital raises and restructuring. This structural dependence on markets or partners increases execution risk, may force unfavorable financing terms, and creates uncertainty around consistent funding for long-duration clinical programs.
Abivax SA News
ABVX FAQ
What was Abivax SA’s price range in the past 12 months?
Abivax SA lowest stock price was €6.55 and its highest was €139.00 in the past 12 months.
What is Abivax SA’s market cap?
Abivax SA’s market cap is €10.20B.
When is Abivax SA’s upcoming earnings report date?
Abivax SA’s upcoming earnings report date is Sep 21, 2026 which is in 78 days.
How were Abivax SA’s earnings last quarter?
Abivax SA released its earnings results on May 22, 2026. The company reported -€0.61 earnings per share for the quarter, beating the consensus estimate of -€0.803 by €0.193.
Is Abivax SA overvalued?
According to Wall Street analysts Abivax SA’s price is currently Undervalued.
Does Abivax SA pay dividends?
Abivax SA does not currently pay dividends.
What is Abivax SA’s EPS estimate?
Abivax SA’s EPS estimate is -0.72.
How many shares outstanding does Abivax SA have?
Abivax SA has 79,782,940 shares outstanding.
What happened to Abivax SA’s price movement after its last earnings report?
Abivax SA reported an EPS of -€0.61 in its last earnings report, beating expectations of -€0.803. Following the earnings report the stock price went up 8.687%.
Which hedge fund is a major shareholder of Abivax SA?
Currently, no hedge funds are holding shares in FR:ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abivax SA
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
ABVX Stock 12 Month Forecast
Average Price Target
€125.00
▲(19.39% Upside)
Technical Analysis
Options Prices
Currently, No data available
---